Holen Sie sich die Stockscreener-App
1.31
2.97%
-0.0401
Handel nachbörslich:
1.31
Schlusskurs vom Vortag:
$1.3501
Offen:
$1.37
24-Stunden-Volumen:
278.10K
Relative Volume:
0.10
Marktkapitalisierung:
$14.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.1606
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
+3.97%
1M Leistung:
-17.09%
6M Leistung:
-46.75%
1J Leistung:
-51.66%
1-Tages-Spanne:
$1.31
$1.4263
1-Wochen-Bereich:
$1.19
$1.4263
52-Wochen-Spanne:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Vergleichen Sie PHIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.31 | 14.53M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
EBIT per share of Phio Pharmaceuticals Corp. – BER:44R1 - TradingView
Will Phio Pharmaceuticals Corp. (44R1) stock beat revenue estimatesMarket Performance Summary & Risk Managed Trade Strategies - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
What technical patterns form on Phio Pharmaceuticals Corp. (44R1) stock chartsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Phio Pharmaceuticals Corp. (44R1) stock rise with strong economyWeekly Trend Summary & Weekly High Return Stock Opportunities - Newser
Phio Pharma (PHIO) Stock Analysis Report | Financials & Insights - Benzinga
How Phio Pharmaceuticals Corp. (44R1) stock compares with market leadersPortfolio Update Summary & Reliable Entry Point Trade Alerts - Newser
What insider trading reveals about Phio Pharmaceuticals Corp. stockProfit Target & Verified Swing Trading Watchlists - Newser
Can Phio Pharmaceuticals Corp. stock continue upward trendMarket Sentiment Report & Real-Time Volume Analysis - Newser
Why retail investors pile into Phio Pharmaceuticals Corp. stockLayoff News & Low Drawdown Trading Strategies - BỘ NỘI VỤ
MSN Money - MSN
How Phio Pharmaceuticals Corp. stock responds to policy changesMarket Risk Report & Fast Gain Swing Alerts - moha.gov.vn
TARC Limited Earnings Review What Investors Need to KnowMid Cap Growth Trends & Free Risk Assessment and Control - earlytimes.in
Phio Pharmaceuticals Completes Enrollment for PH-762 Trial - TipRanks
Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 - TradingView
Phio Pharmaceuticals Corp. Announces Completion of Enrollment in Phase 1B Clinical Trial of Intasyl Sirna Lead Compound Ph-762 - marketscreener.com
Phio completes enrollment in Phase 1b trial of skin cancer therapy - Investing.com Australia
Phio completes enrollment in Phase 1b trial of skin cancer therapy By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile
Phio Pharmaceuticals (NASDAQ: PHIO) Reports PH-762 Data With 6 Complete Responses - Stock Titan
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
It is Poised to be a Bull Market for Phio Pharmaceuticals Corp (PHIO) - Setenews
What is HC Wainwright’s Forecast for PHIO FY2025 Earnings? - Defense World
How higher bond yields impact Phio Pharmaceuticals Corp. (44R1) stockJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
Developing predictive dashboards with Phio Pharmaceuticals Corp. dataQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Phio Pharmaceuticals Corp files for offering of up to 11.8 million common shares by the Selling StockholdersSEC filing - MarketScreener
[S-3] Phio Pharmaceuticals Corp. Shelf Registration Statement | PHIO SEC FilingForm S-3 - Stock Titan
How Phio Pharmaceuticals Corp. (44R1) stock trades under stagflationMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Published on: 2025-11-20 05:56:20 - newser.com
How Phio Pharmaceuticals Corp. stock performs in rate cut cyclesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Is Phio Pharmaceuticals Corp. (44R1) stock protected from inflationJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock trades in high volatilityEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
Published on: 2025-11-19 20:52:55 - newser.com
Published on: 2025-11-19 18:13:16 - newser.com
Published on: 2025-11-19 16:59:54 - newser.com
Published on: 2025-11-19 16:50:52 - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock correlates with oil marketsDay Trade & Free Risk Controlled Daily Trade Plans - newser.com
Insider Buying: Robert Bitterman Acquires Additional Shares of P - GuruFocus
Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 By Investing.com - Investing.com Canada
Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 - Investing.com India
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):